CoChat
Sign Up
Cited by 159Breast Cancer Treatment StudiesBreast Lesions and CarcinomasMRI in cancer diagnosis

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes

Diego, Emilia J., McAuliffe, Priscilla F., Soran, Atilla, McGuire, Kandace P., Johnson, Ronald R., Bonaventura, Marguerite, Ahrendt, Gretchen M.·2016·Annals of Surgical Oncology
DOI 10.1245/s10434-015-5052-8
Open this paper in CoChat — free account

Abstract

Background Neoadjuvant chemotherapy (NAC) downstages axillary disease in 55 % of node-positive (N1) breast cancer. The feasibility and accuracy of sentinel lymph node biopsy (SLNB) after NAC for percutaneous biopsy-proven N1 patients who are clinically node negative (cN0) by physical examination after NAC is under investigation. ACOSOG Z1071 reported a false-negative rate of <10 % if ≥3 nodes are removed with dual tracer, including excision of the biopsy-proven positive lymph node (BxLN). We report our experience using radioactive seed localization (RSL) to retrieve the BxLN with SLNB (RSL/SLNB) for cN0 patients after NAC.Methods We performed a retrospective review of a single-institution, prospectively maintained registry for the years 2013 to 2014. Patients with BxLN who received NAC and had RSL/SLNB were identified. All BxLNs were marked with a radiopaque clip before NAC to facilitate RSL.Results Thirty patients with BxLN before NAC were cN0 after NAC and underwent RSL/SLNB. Median age was 55 years. Disease stage was IIA-IIIB. Twenty-nine of 30 had ductal cancer (12 triple negative and 16 HER-2 positive). One to 11 nodes were retrieved. Twenty-nine of 30 BxLN were successfully localized with RSL. Note was made of the BxLN-containing isotope and/or dye in 22 of 30. Nineteen patients had no residual axillary disease; 11 had persistent disease. All who remained node positive had disease in the BxLN.Conclusions RSL/SLNB is a promising approach for axillary staging after NAC in patients whose disease becomes cN0. The status of the BxLN after NAC predicted nodal status, suggesting that localization of the BxLN may be more accurate than SLNB alone for staging the axilla in the cN0 patient after NAC.

Overview

Integrity signals

Registry

Crossref · 10.1245/s10434-015-5052-8

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Caudle AS, Yang WT, Mittendorf EA, et al. Targeted axillary dissection improves axillary evaluation following neoadjuvant chemotherapy in node positive breast cancer. Paper presented at: 68th SSO Annual Cancer Symposium; March 25–28, 2015; Houston, TX.

Cited by

Sorted by citations

Related

Metadata

Authors
Diego, E. J., McAuliffe, P. F., Soran, A., McGuire, K. P., Johnson, R. R., Bonaventura, M., & Ahrendt, G. M.
Affiliations
  • University of Pittsburgh (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Diego, Emilia J.
ORCID
Venue
Annals of Surgical Oncology
Publisher
Springer Science and Business Media LLC
Published
2016-01-04
Volume
23
Issue
5
Pages
1549-1553
ISSN
  • 1068-9265 (ISSN-L)
  • 1534-4681
DOI
10.1245/s10434-015-5052-8
OpenAlex
W2230554567
Cited by
159
References
28
Citations by year
2026: 5 · 2025: 11 · 2024: 16 · 2023: 16 · 2022: 15 · 2021: 21 · 2020: 19 · 2019: 15 · 2018: 25 · 2017: 12 · 2016: 4
FWCI
7.78
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Annals of Surgical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P50CA058223)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Keywords
breast cancer, neoadjuvant chemotherapy, axillary staging, sentinel lymph node biopsy, radioactive seed localization, axillary lymph node metastasis, ductal carcinoma, triple-negative breast cancer, HER2-positive breast cancer
MeSH terms
Sentinel Lymph Node, Adult, Aged, Axilla, Breast Neoplasms, Female, Follow-Up Studies, Humans, Iodine Radioisotopes, Middle Aged, Neoplasm Seeding, Neoplasm Staging, Pilot Projects, Prognosis, Prospective Studies, Radionuclide Imaging, Retrospective Studies, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Radiopharmaceuticals, Neoadjuvant Therapy, Sentinel Lymph Node Biopsy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review